Table of Contents
What a COA Actually Tells You (And What It Hides)
A Certificate of Analysis is a document issued by a testing laboratory that reports the results of quality testing performed on a specific batch of material. For peptide APIs, the COA typically covers identity, purity, potency, and safety parameters. It is the primary quality assurance document in peptide procurement — the single most important piece of paper in any supplier relationship.
However, a COA has inherent limitations that every buyer should understand. It represents a snapshot of a single sample from a single batch at a single point in time. It does not guarantee that the rest of the batch is identical (sampling bias), it does not predict stability over time (degradation can occur post-testing), and it is only as reliable as the laboratory, methodology, and integrity behind it.
A COA from a supplier is also inherently conflicted: the supplier has a commercial interest in the results showing compliance. This is why independent third-party testing is so important — it removes the conflict of interest and provides legally defensible quality data.
Testing Methods: HPLC, LC-MS, and Beyond
HPLC (High-Performance Liquid Chromatography)
HPLC is the industry standard for measuring peptide purity. It works by dissolving the sample and pumping it through a column packed with specialized material (typically C18 reversed-phase). Different components of the sample interact differently with the column material, causing them to elute at different times. A UV detector measures the amount of each component as it exits the column.
The result is a chromatogram — a graph showing peaks at different retention times. The purity is calculated as the area percentage of the target peptide peak relative to all detected peaks. A purity of 98.3% means 98.3% of the UV-detectable material in the sample is the target peptide, with the remaining 1.7% being impurities.
What HPLC tells you: Relative purity, the presence and abundance of impurities, and batch-to-batch consistency when comparing chromatographic profiles.
What HPLC does not tell you: Whether the major peak is actually the correct peptide (a different peptide of similar hydrophobicity could co-elute), the exact identity of impurities, or the presence of non-UV-absorbing contaminants like salts, counterions, or water.
LC-MS (Liquid Chromatography-Mass Spectrometry)
LC-MS combines HPLC separation with mass spectrometry detection. After compounds are separated by the LC column, they enter the mass spectrometer, which measures their molecular weight. This provides a critical additional dimension of information: identity confirmation.
For peptides, LC-MS confirms that the major component has the expected molecular weight — matching the theoretical molecular weight calculated from the amino acid sequence. This is essential because HPLC alone cannot distinguish between the target peptide and a deletion sequence impurity that happens to co-elute.
What LC-MS tells you: Molecular weight of the target compound (confirming identity), molecular weight of impurity peaks, and detection of modifications like oxidation (+16 Da), deamidation (+1 Da), or incomplete deprotection.
What LC-MS does not tell you (without additional methods): Sequence information (which amino acids are where — requires MS/MS or sequencing), biological activity or potency, and endotoxin or microbial contamination levels.
Additional Testing Methods
- Amino Acid Analysis (AAA): Hydrolysis of the peptide followed by quantification of individual amino acids. Confirms that the amino acid composition matches the expected sequence. Does not confirm sequence order — only composition.
- Endotoxin Testing (LAL): The Limulus Amebocyte Lysate assay detects bacterial endotoxins. Critical for injectable-grade materials because endotoxins can cause fever, septic shock, and death. Specification is typically <5 or <10 EU/mg for injectable peptides.
- Residual Solvent Testing: Gas chromatography measurement of organic solvents remaining from the synthesis and purification process. Must meet ICH Q3C limits (e.g., <410 ppm for acetonitrile, <5000 ppm for acetone).
- Water Content (Karl Fischer): Measures moisture content in the lyophilized peptide. Important for stability — high water content can accelerate degradation. Typical specification: <6-8%.
- Sterility Testing: For sterile products, confirms absence of viable microorganisms using membrane filtration or direct inoculation methods.
- Peptide Content: Quantifies the actual peptide as a percentage of the total material (including salts, water, and counterions). A peptide with 98% HPLC purity might have only 80% peptide content because the remaining 20% is TFA salt and water. This distinction matters for accurate dosing.
For a detailed HPLC vs LC-MS comparison: HPLC vs LC-MS: Which Purity Test Matters?
How to Read a COA Line by Line
A well-structured COA should contain the following elements. Here is what to check for each:
| Element | What to Check | Red Flag If... |
|---|---|---|
| Lab Name & Contact | Named, contactable, verifiable lab with accreditation number | Generic "Quality Control Dept" or no contact info |
| Client/Requester | Should match the supplier name on your purchase order | Different company name than your supplier |
| Product Identification | Correct peptide name, CAS number, molecular formula, molecular weight | Missing CAS number or molecular formula |
| Lot/Batch Number | Unique per batch; must match your product label | Same lot number across different orders months apart |
| Test Date | Recent relative to manufacturing date and your order | Dated years before your purchase |
| HPLC Purity | Specific value with decimal (e.g., 98.7%); method description included | Round numbers only (99.00%); no method info |
| MS Identity | Observed MW matches theoretical within ±1 Da (for peptides <5 kDa) | No MS data included; only HPLC |
| Endotoxin | Below specification; tested by LAL method | No endotoxin testing for injectable material |
| Appearance | Matches expected form (white/off-white lyophilized powder) | Not tested or "N/A" |
| Chromatogram | Actual HPLC trace image included showing the peak | Number only, no chromatogram image |
| Authorization | Signed or electronically authorized by named quality officer | Unsigned; no authorizing individual named |
Third-Party vs In-House Testing
In-house testing by the manufacturer has value — it demonstrates the manufacturer has analytical capability and ongoing quality control processes. Every GMP manufacturer performs in-house testing as part of their batch release procedures. This is expected and appropriate.
However, in-house results alone should not be the basis for accepting incoming materials. The manufacturer has a commercial interest in every batch passing specification. This does not mean they fabricate results — reputable manufacturers have strong quality cultures — but it does mean the testing lacks the independence that provides maximum confidence.
Independent third-party testing removes this conflict of interest. The testing lab has no relationship with the supplier and no interest in the outcome. Their results are what they are.
When Third-Party Testing Is Essential
- Initial supplier qualification (every time)
- First order from a new supplier
- Any batch where in-house identity testing shows unexpected results
- After any quality event or supplier CAPA
- Complex or high-value peptides (semaglutide, tirzepatide)
- Injectable-grade materials destined for patient use
Red Flags in COA Documentation
Common warning signs that warrant deeper investigation or supplier disqualification:
- Recycled lot numbers: Same COA provided for different orders placed months apart. Legitimate manufacturers assign unique lot numbers to every production batch.
- Missing chromatograms: A COA that reports HPLC purity as "98.5%" without including the actual chromatogram image is incomplete. The chromatogram is where you see the actual data — without it, you are taking the number on faith.
- Generic templates: COAs that look identical across different peptide products (same layout, same testing lab, only the compound name and purity number changed). Professional laboratories use consistent formatting, but the data should clearly vary between different compounds.
- Perfect round numbers: Real analytical data includes decimal places. A purity of "98.37%" looks like real data. A purity of "99.00%" looks fabricated. Nature does not produce perfectly round results.
- No lab accreditation reference: A legitimate testing lab will reference their ISO 17025 accreditation (or equivalent) on every COA.
- Unsigned documents: Every COA should be authorized by a named individual. "Quality Department" is not a valid authorization.
- Inconsistent impurity profiles: If you compare COAs from multiple batches of the same peptide from the same manufacturer, the impurity profile should be broadly consistent. Dramatically different impurity patterns between batches may indicate the product is coming from different manufacturers or processes.
- Suspiciously high purity for complex peptides: A 40-amino-acid peptide claiming 99.9% purity is almost certainly overstated. The longer and more complex the peptide, the more realistic impurity levels become.
See also: How to Spot a Fake Peptide COA in 60 Seconds
Purity Benchmarks by Peptide Category
Understanding realistic purity ranges helps identify both quality products and suspicious claims:
| Peptide Category | Typical Length | Research Grade | Pharma Grade | Unrealistic |
|---|---|---|---|---|
| Short peptides (<10 aa) | 3-9 aa | ≥95% | ≥98% | >99.9% |
| Medium peptides (10-30 aa) | 10-30 aa | ≥93% | ≥96% | >99.5% |
| Long peptides (30-50 aa) | 30-50 aa | ≥90% | ≥95% | >99% |
| Modified peptides (lipidated, PEGylated) | Varies | ≥90% | ≥95% | >99% |
| Semaglutide (31 aa, C18 fatty acid) | 31 aa + mod | ≥93% | ≥96% | >99.5% |
Verification Platforms and Tools
As the peptide market matures, automated verification platforms are emerging that cross-reference COA data against laboratory databases, flag inconsistencies, and maintain quality records across suppliers and batches. These tools represent the future of scalable quality assurance for organizations handling multiple suppliers and products.
Key features to look for in a COA verification platform: automated extraction of COA data fields, cross-referencing against known laboratory databases, trend analysis across batches (detecting drift in purity or impurity profiles), alert systems for expired certificates or overdue re-testing, and integration with procurement and inventory management systems.
Our COA Verification Tool provides a starting point for evaluating COA data against known standards.
Building a COA Management System
For organizations procuring peptides at scale, individual COA review isn't sufficient — you need a systematic approach to COA management that scales with your supplier relationships and order volume.
Document Management
Every COA received should be logged in a document management system with at minimum: supplier name, compound name, lot/batch number, receipt date, test date, key results (purity, identity confirmation, endotoxin), pass/fail determination, and the reviewer's name and date. Cloud-based quality management systems like MasterControl, Veeva Vault, or even well-structured Google Drive/SharePoint folders can serve this purpose depending on your organization's size and regulatory requirements.
Trend Analysis
One of the most powerful uses of COA data is trend analysis across batches. By tracking HPLC purity over time for each supplier-peptide combination, you can identify:
- Purity drift: A gradual decline in purity across successive batches may indicate process degradation, raw material quality changes, or equipment issues at the manufacturer.
- Impurity pattern changes: If the chromatographic impurity profile shifts significantly between batches, it may indicate a process change, different raw material source, or even a different manufacturing site being used.
- Consistency: Highly consistent results across batches are a positive quality signal. Erratic results suggest an unstable process.
- Bias detection: If every batch from a supplier shows exactly the same purity (e.g., 98.5% every time), the results may be fabricated rather than measured. Real analytical data shows natural batch-to-batch variation.
Incoming Material Testing Protocol
Your incoming material testing protocol should define:
- What to test: At minimum, identity testing (confirming the material is the correct peptide) should be performed on every incoming lot. Full COA verification testing (purity, endotoxin, etc.) should be performed on a risk-based schedule.
- When to test: Before releasing any material for compounding or use. Quarantine incoming materials until testing is complete.
- Who tests: Your in-house lab (if you have one) or a contracted third-party laboratory. The testing entity must be independent of the supplier.
- Acceptance criteria: Define what constitutes a passing result for each test. These should match or exceed your supplier's specification.
- Failure procedures: What happens when a material fails incoming testing? Define the process for quarantine, investigation, supplier notification, CAPA, and potential lot rejection.
Dispute Resolution
When your incoming test results disagree with the supplier's COA, a structured dispute resolution process prevents the disagreement from becoming adversarial:
- Review methods: Ensure both parties are using comparable analytical methods. Differences in HPLC column, gradient, or detection wavelength can cause legitimate result differences.
- Retain samples: Both parties should retain reserve samples from the disputed lot for potential re-testing.
- Independent arbitration: If the dispute cannot be resolved through discussion, submit retained samples to a mutually agreed-upon independent laboratory. This lab's results serve as the definitive determination.
- Root cause analysis: Regardless of the outcome, investigate why the discrepancy occurred. Was it a method difference, a sampling issue, or a genuine quality problem?
Advanced COA Interpretation
Reading HPLC Chromatograms
The chromatogram is the most information-dense element of any peptide COA. Here's what to look for beyond the headline purity number:
- Main peak shape: The target peptide peak should be sharp and symmetrical. Tailing, fronting, or shoulder peaks may indicate co-eluting impurities that inflate the apparent purity.
- Baseline: A flat, stable baseline indicates good chromatographic conditions. A noisy or drifting baseline suggests system problems that may affect result accuracy.
- Impurity peaks: Count and note the impurity peaks. For a typical peptide synthesis, you expect to see deletion sequences (earlier-eluting peaks from missed coupling steps) and oxidized forms (slightly later-eluting). Unusual or unexpected peaks warrant investigation.
- Integration: Check that the peak integration (the shaded area under each peak) appears reasonable. Some labs manipulate integration parameters to exclude impurity peaks — this is a form of data manipulation that inflates apparent purity.
- Retention time: The main peak should elute at a retention time consistent with the peptide's known hydrophobicity. If you're familiar with a particular peptide's expected retention time, a significant shift may indicate a different compound or significantly different analytical conditions.
Interpreting Mass Spectrometry Data
Mass spectrometry data on a COA typically shows the observed molecular weight (MW) compared to the theoretical MW. Key interpretation points:
- Mass accuracy: For peptides under 5,000 Da, the observed MW should match theoretical within ±1 Da on standard instruments. Higher-resolution instruments (LC-QTOF) should match within ±0.5 Da or better.
- Multiple charge states: In electrospray ionization (ESI-MS), peptides form multiply-charged ions. You may see peaks labeled [M+2H]²⁺, [M+3H]³⁺, etc. All should deconvolute to the same molecular weight.
- Adducts: Sodium adducts ([M+Na]⁺) appear at +22 Da from the protonated molecular ion. Their presence is normal but excessive sodium adduct intensity may indicate salt contamination.
- Deamidation: A +1 Da mass shift from the expected MW may indicate deamidation of asparagine or glutamine residues — a common degradation pathway that should be monitored.
- Oxidation: A +16 Da shift indicates methionine oxidation, another common modification that may indicate degradation or suboptimal manufacturing/storage conditions.
Verify Your COAs Now
Upload or enter COA data to check against quality benchmarks and identify red flags.
Try COA Verification Tool →